Intervention

Semaglutide weekly injection

ClinicalTrials.gov intervention label

Clinical trials6
Recruiting0
Common conditions2
Lead sponsors shown2

Clinical trials

6 shown
Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric SurgeryNCT07859176 · 2026-10-01
NOT_YET_RECRUITING
Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight GainNCT07859163 · 2026-10-01
NOT_YET_RECRUITING
Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric SurgeryNCT07859189 · 2026-10-01
NOT_YET_RECRUITING
Semaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m² or HigherNCT07859137 · 2026-10-01
NOT_YET_RECRUITING
Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE)NCT07859150 · 2026-10-01
NOT_YET_RECRUITING
Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolusNCT06057077 · 2024-01-01
UNKNOWN

Trial status mix

NOT_YET_RECRUITING5
UNKNOWN1

Phase mix

PHASE45
PHASE11
PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.